Antisense Oligonucleotides Targeting miR-27b for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy and other neurological disorders are inadequate, with existing anti-epileptic drugs ineffective for a third of patients and lacking prophylactic or neuroprotective options, and microRNA-27b (miR-27b) plays a critical role in neurological conditions but has no specific therapeutic targeting.
Innovation Solution
Development of potent antisense oligonucleotides complementary to miR-27b, specifically designed as LNA/DNA mixmers with phosphorothioate internucleotide linkages, to inhibit miR-27b activity, thereby upregulating the Nrf2/ARE pathway, which is beneficial for treating CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-epileptic drugs are used, then seizures are controlled in two-thirds of patients, but the treatment is ineffective for one-third of patients and causes serious side effects
Solution Approach 1:
The invention changes the therapeutic parameter from conventional anti-epileptic drugs to antisense oligonucleotides targeting miR-27b, fundamentally altering the mechanism of action to achieve seizure control without the side effects and resistance issues associated with traditional drugs
Solution Approach 2:
The invention extracts and targets the specific molecular mechanism (miR-27b) involved in epilepsy pathogenesis, rather than using broad-spectrum conventional drugs, thereby achieving selective therapeutic action that avoids off-target side effects
2Reliability
If existing anti-epileptic treatments are used, then symptomatic seizure control is achieved, but prophylactic treatment and neuroprotection are unavailable
Solution Approach 1:
The antisense oligonucleotide therapy against miR-27b serves multiple functions: it provides prophylactic treatment by preventing epileptogenesis, offers neuroprotection during status epilepticus, and treats acute neurological injuries, thereby extending the treatment scope beyond symptomatic seizure control
Solution Approach 2:
The invention enables preliminary prophylactic action by targeting miR-27b before epileptic seizures establish themselves, preventing the development of epilepsy following brain injury rather than merely treating established seizures
3Adaptability or versatility
If microRNA-27b is targeted with conventional methods, then therapeutic effects may be achieved, but specific potent inhibition is not realized
Solution Approach 1:
The invention employs composite antisense oligonucleotide structures combining different nucleotide components and chemical modifications to achieve both specific targeting of miR-27b and potent inhibition, overcoming the limitations of conventional single-component approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively downregulate miR-27b activity, inducing the Nrf2/ARE pathway, providing therapeutic benefits for epilepsy, neurodegenerative disorders, and other CNS-related conditions by reducing oxidative stress, inflammation, and apoptosis.
Implementation Method 1
antisense oligonucleotides complementary to miR-27b...capable of modulating the activity of miR-27b
Data Source
AI summary
The present invention provides antisense oligonucleotides complementary to miR-27b, capable of potently inhibiting the activity of miR-27b. Such compounds are useful as pharmaceuticals for treatment of diseases in the CNS or in the PNS including neurological diseases.